All In Biotech

Drug Trial Radar · NCT00423644

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Jan 2007

Primary completion

Dec 21, 2007

Study completion Dec 21, 2008

Sponsor

Lead sponsor
Alaunos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Conditions

  • Multiple Myeloma

Interventions

  • DarinaparsonDrug

    420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response RateTime frame: 6 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Glendale, Arizona

  • Site not named

    Santa Barbara, California

  • Site not named

    Santa Rosa, California

  • Site not named

    West Hollywood, California

  • Site not named

    Bethesda, Maryland

  • Site not named

    Buffalo, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Sioux Falls, South Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.